Pure Global AI
NCT06263959Recruiting

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Fujian Akeylink Biotechnology Co., Ltd.Phase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Chronic Hepatitis B
Drug/Device/Intervention
GST-HG131
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Fujian Akeylink Biotechnology Co., Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 2
Start date
Dec 29, 2023
End date
Nov 01, 2024
Enrollment
45 participants
Primary outcome

Change from Baseline in HBsAg levels

Summary

A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the
 safety and efficacy of GST-HG131 tablets in patients with chronic hepatitis B

ICD-10 classifications
Acute hepatitis BChronic viral hepatitis B without delta-agentAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agent : other and unspecified phaseChronic viral hepatitis B without delta-agent : immune-tolerant phase
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06263959
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06263959 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fujian Akeylink Biotechnology Co., Ltd. and is currently Recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 45 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.